PURPOSE: @entity136 / @entity6023 -based combination shows anti- @entity5 activity for the treatment of metastatic @entity0 , but there is a debate regarding the advantages of @entity136 and @entity6023 regimens as a first-line or second-line treatment for metastatic @entity0 . Here we conducted a systematic review and meta-analysis to compare the efficacy and @entity137 for @entity1 receiving chemotherapy with or without GT-based regimens. METHODS: The randomized controlled trials were performed by searching Pubmed, MEDLINE, EMBASE, and conference proceedings. We identified eight randomized controlled trials and then extracted and combined the data using to calculate hazard ratios (HR). The primary outcomes were progression-free survival (PFS) and @entity1054 ( @entity1054 ). The secondary outcomes were @entity1349 ( @entity1349 ) and acute @entity137 . A meta-analysis was performed using Review Manager Version 4.2. RESULTS: Eight eligible trails were identified. These studies involved 2234 @entity1 with metastatic @entity0 , (1122 @entity1 received GT-based combination regimen and 1112 @entity1 received a regimen without the combination). A fixed-effects model meta-analysis showed that ORR and @entity1054 are superior for GT-treated @entity1 ORR (OR   =   1.28, 95% CI 1.07-1.53), @entity1054 (HR   =   0.80; 95% CI 0.71-0.89). And GT-based combination significantly improved @entity1349 in the first-line subgroup (HR   =   0.84; 95% CI 0.71-0.99). However, there were significant differences regarding acute hematological @entity137 , particularly @entity882 . CONCLUSION: @entity136 / @entity6023 -treated @entity1 with metastatic @entity0 showed a significant improvement in the ORR, @entity1054 and @entity1349 (first-line background) compared to @entity1 not treated with the combination regimen.

A systematic review of @entity136 and @entity6023 combination therapy randomized trials for metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
